The approval makes Wegovy the only GLP-1 therapy cleared to treat adults with metabolic dysfunction-associated ...

The U.S. Food and Drug Administration approved the obesity drug Wegovy for people with the chronic liver disease known as ...

In a significant breakthrough for the treatment of liver disease, Novo Nordisk's Wegovy has received U.S. approval for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) in ...

MDGL wins EU nod for Rezdiffra as the first and only approved MASH therapy. The drug's launch in Europe is expected in the fourth quarter of 2025.

Madrigal Pharmaceuticals’ Rezdiffra has been approved in Europe for the treatment of MASH with moderate to advanced liver ...

Ozempic, chemically known as semaglutide, is now the first approved treatment in Canada for type 2 diabetes and to slow ...

Fresh & Ready Foods, LLC, recalled a few of their ready-to-eat products, including sandwiches and other snack items, over ...

NEW YORK — (AP) — Wall Street held near its record heights on Monday, ahead of a week likely to be dominated by updates from ...

In an effort to address the state’s obesity epidemic and subsequently address the health effects associated with it, the Mississippi Legislature is considering allowing GLP-1 medications such as ...

This week, medication savings platform GoodRx announced a partnership with Novo Nordisk – the company behind Ozempic and ...

Read the latest research on diseases and conditions, symptoms, new treatment options and more. Updated daily.